Category Archives: Public Policy

Latest From Public Policy

CNN: Sandy’s Story

scientist-eyedropper

CNN launched a new series profiling Sandy Halperin, a dentist and Harvard assistant professor, to raise awareness for the devastating impact of Alzheimer’s disease on a patient and his family. Producer Stephanie Smith describes Sandy’s Story as ‘an unprecedented look at the cruel journey of a vibrant, once healthy man as he gradually loses his memory.’ Halperin was diagnosed with early stage Alzheimer’s disease at age 60. The in-depth package explores the day-to-day reality of Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Patients Suffering from Gaucher’s Disease Deserve Better

scientist-eyedropper

Gaucher Disease is one of the over 6,000 rare diseases that affect patients worldwide, representing a frontier of unmet medical need [NCATS, NIH]. The challenges for drug development generally—long and costly research and development timelines—are exacerbated by the inherently small patient populations affected by rare diseases. These patients can be difficult to identify and geographically dispersed and their clinical presentation can be quite disparate, complicating the design and recruitment for clinical trials used to determine Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Participating in IDSA Stakeholder Group on Antimicrobial Resistance

MRSA

BIO will be participating in a newly formed partnership which will work collaboratively to inform federal policy and find ways to better combat the growing crisis of antimicrobial resistance. Launched yesterday by the Infectious Diseases Society of America (IDSA), which also released foundation principles for the group, the U.S. Stakeholder Forum on Antimicrobial Resistance (S-FAR) will hold its inaugural meeting in Philadelphia next month on October 9th. BIO joins more than 75 other national organizations Read More >

Health, Public Policy  |  1 Comment  |  Email This Post
Tags: , , , ,

BIO Submits Amicus Briefs in Braintree v. Novel, Gilead v. Natco, and Bristol-Myers Squibb v. Teva Pharmaceuticals

scientist-eyedropper

BIO has submitted briefs in three recent cases which could significantly impair drug and biotechnology efforts, urging reconsideration and review from both the Supreme Court and the U.S. Court of Appeals for the Federal Circuit. BIO, in conjunction with PhRMA, submitted an amicus brief to the Supreme Court in Braintree v. Novel, arguing that the majority’s decision creates an unpredictable climate for patent claims. Vacating the prior claim construction precedent which had repeatedly interpreted “a” Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

PTO Patent Examinations in the wake of Mayo and Myriad

stopped-media-115x76

Biotech patent applicants are finding themselves in uncharted waters.   After the Supreme Court’s decisions in Mayo Collaborative Svs. v. Prometheus Labs and Ass’n for Molecular Pathology v. Myriad Genetics, companies have been trying to understand how these decisions will impact the industry. A recent study supported by BIO, in collaboration with Bloomberg BNA and the law firm of Robins, Kaplan, Miller & Ciresi analyzed how Mayo and Myriad have changed patent eligibility for biotechnology. Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,